Nirma's open offer to buy more stake in Glenmark Life to start on Feb 15

The development follows Nirma's deal to acquire 75 per cent stake in Glenmark Life Sciences for Rs 5,651.5 crore agreed in September last year

Nirma
Press Trust of India New Delhi
2 min read Last Updated : Feb 09 2024 | 7:21 PM IST

Nirma Ltd will kick off a Rs 1,343.05-crore open offer next week to acquire an additional 17.33 per cent stake from public shareholders of Glenmark Life Sciences Ltd, according to a regulatory filing.

The development follows Nirma's deal to acquire 75 per cent stake in Glenmark Life Sciences for Rs 5,651.5 crore agreed in September last year.

The open offer is being made to the public shareholders to acquire up to 2.13 crore equity shares representing 17.33 per cent of the voting share capital at an offer price of Rs 631.20 per share aggregating to a total consideration of up to Rs 1,343.05 crore, said the letter of offer by Nirma shared on BSE by Glenmark Life Sciences.

The offer shares include the entire public shareholding in the target company (over 2.1 crore shares) and 2.63 lakh vested ESOPs, it added.

The opening date (commencement of the tendering period) for the open offer has been fixed on February 15, 2024 and will close on February 29, 2024, as per the letter of offer, the letter said.

Last year in September, Glenmark Pharmaceuticals board had approved divestment of 75 per cent stake in its subsidiary Glenmark Life Sciences to Nirma Ltd for Rs 5,651.5 crore.

The parties had signed a definitive agreement, under which the Mumbai-based drug maker agreed to offload a 75 per cent stake in Glenmark Life Sciences (GLS) to Nirma Ltd at a price of Rs 615 per share and retaining just a 7.84 per cent stake in GLS.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :NirmaNirma GroupGlenmark Life SciencesFMCG sector

First Published: Feb 09 2024 | 7:21 PM IST

Next Story